Amgen

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Amgen and other ETFs, options, and stocks.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
24,200
Employees24,200
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
24,200
Employees24,200

AMGN Key Statistics

Market cap
151.16B
Market cap151.16B
Price-Earnings ratio
22.84
Price-Earnings ratio22.84
Dividend yield
2.72
Dividend yield2.72
Average volume
2.90M
Average volume2.90M
High today
$287.42
High today$287.42
Low today
$281.69
Low today$281.69
Open price
$286.62
Open price$286.62
Volume
2.61M
Volume2.61M
52 Week high
$296.67
52 Week high$296.67
52 Week low
$207.36
52 Week low$207.36

AMGN News

Investor's Business Daily 13h
Mirati Therapeutics Crashes As The Cancer Rivalry With Amgen Heats Up

Mirati Therapeutics (MRTX) said almost half of patients responded to its lung cancer regimen, but MRTX stock crashed Tuesday as investors questioned whether it...

Mirati Therapeutics Crashes As The Cancer Rivalry With Amgen Heats Up
Benzinga 1d
Amgen Unusual Options Activity For December 05 - Amgen - Benzinga

A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen AMGN we detected 13 strange trades....

Amgen Unusual Options Activity For December 05 - Amgen - Benzinga
Investor's Business Daily 2d
Horizon Topples After J&J Pulls Out Of Bidding War, Leaving Amgen, Sanofi

Horizon Topples After J&J Pulls Out Of Bidding War, Leaving Amgen, Sanofi Johnson & Johnson dropped out of the bidding process for Horizon Therapeutics, pushin...

Horizon Topples After J&J Pulls Out Of Bidding War, Leaving Amgen, Sanofi

Analyst ratings

61%

of 23 ratings
Buy
17.4%
Hold
60.9%
Sell
21.7%

AMGN Earnings

$0.00
$1.57
$3.13
$4.70
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
Estimated
per share
Estimated per share
Actual
Expected Feb 6, After Hours
ActualExpected Feb 6, After Hours

More AMGN News

Simply Wall St 3d
Amgen Seems To Use Debt Quite Sensibly - Simply Wall St

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about......

Amgen Seems To Use Debt Quite Sensibly - Simply Wall St
Reuters 3d
Amgen says experimental obesity drug has promising durability - Reuters

LOS ANGELES, Dec 3 (Reuters) - Amgen Inc's (AMGN.O) experimental obesity drug demonstrated promising durability trends in an early trial, paving t...

Amgen says experimental obesity drug has promising durability - Reuters
Simply Wall St 5d
Amgen shareholders have earned a 14% CAGR over the last five years

Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the market average. And the truth is, you can...

Amgen shareholders have earned a 14% CAGR over the last five years
Benzinga 5d
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key - Benzinga

Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year...

Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key - Benzinga
Investor's Business Daily 6d
Amgen Is The Underdog In Obesity Treatment — But It's Creeping Up On Novo Nordisk, Eli Lilly

Amgen stock — which is already trading near a record high — could get a fresh boost Thursday after the company unveiled promising results for its obesity treatm...

Amgen Is The Underdog In Obesity Treatment — But It's Creeping Up On Novo Nordisk, Eli Lilly
Bloomberg 6d
Amgen Has a Contender in the Weight-Loss Drug Wars - Bloomberg

The first detailed look at data on Amgen Inc.’s obesity drug offers a promising glimpse into the future of weight-loss treatment. How promising? Sure, it’s earl...

Amgen Has a Contender in the Weight-Loss Drug Wars - Bloomberg
Yahoo Finance 6d
insitro Appoints Philip Tagari, Industry-Leading Scientist and Drug Hunter, as Chief Scientific Officer - Yahoo Finance

Tagari joins insitro from Amgen, where he led the discovery of multiple important new therapies across therapeutic areas and modalities for more than two decade...

insitro Appoints Philip Tagari, Industry-Leading Scientist and Drug Hunter, as Chief Scientific Officer - Yahoo Finance
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.